JP2021525711A5 - - Google Patents
Info
- Publication number
- JP2021525711A5 JP2021525711A5 JP2020565929A JP2020565929A JP2021525711A5 JP 2021525711 A5 JP2021525711 A5 JP 2021525711A5 JP 2020565929 A JP2020565929 A JP 2020565929A JP 2020565929 A JP2020565929 A JP 2020565929A JP 2021525711 A5 JP2021525711 A5 JP 2021525711A5
- Authority
- JP
- Japan
- Prior art keywords
- activator
- fragment
- dsshaftldelr
- seq
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677013P | 2018-05-27 | 2018-05-27 | |
| US62/677,013 | 2018-05-27 | ||
| PCT/US2019/033012 WO2019231725A2 (en) | 2018-05-27 | 2019-05-18 | Treatment of gaucher disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525711A JP2021525711A (ja) | 2021-09-27 |
| JP2021525711A5 true JP2021525711A5 (https=) | 2022-05-02 |
Family
ID=68697612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565929A Pending JP2021525711A (ja) | 2018-05-27 | 2019-05-18 | ゴーシェ病の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210113703A1 (https=) |
| EP (1) | EP3796928A4 (https=) |
| JP (1) | JP2021525711A (https=) |
| KR (1) | KR20210024492A (https=) |
| CN (1) | CN112512558A (https=) |
| AU (1) | AU2019276882A1 (https=) |
| CA (1) | CA3101097A1 (https=) |
| WO (1) | WO2019231725A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210355468A1 (en) * | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
| US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| KR102593930B1 (ko) | 2023-04-18 | 2023-10-25 | 주식회사 한국스크랩 | 친환경 폐 알루미늄 박리 자동화 시스템 |
| CN119074730A (zh) * | 2024-08-28 | 2024-12-06 | 北京大学第一医院(北京大学第一临床医学院) | 葡萄糖神经酰胺合酶抑制剂在制备预防和/或治疗代谢应激性肝脏损伤相关疾病产品中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057179A2 (en) * | 2002-01-11 | 2003-07-17 | Biomarin Pharmaceutical, Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| NZ713967A (en) * | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| CA3140959A1 (en) * | 2009-11-27 | 2011-06-03 | Genzyme Corporation | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| CN103747807B (zh) * | 2011-07-05 | 2016-12-07 | 比奥阿赛斯技术有限公司 | P97‑抗体缀合物和使用方法 |
| EP2814838A1 (en) * | 2012-02-19 | 2014-12-24 | Protalix Ltd. | Oral unit dosage forms and uses of same for the treatment of gaucher disease |
| AU2014243816B2 (en) * | 2013-03-13 | 2019-01-31 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| AU2015252906C1 (en) * | 2014-05-01 | 2020-09-17 | Bioasis Technologies Inc. | p97-polynucleotide conjugates |
| US20180009898A1 (en) * | 2016-07-07 | 2018-01-11 | Bioasis Technologies, Inc. | Antibodies against p97 and conjugates thereof |
-
2019
- 2019-05-18 AU AU2019276882A patent/AU2019276882A1/en not_active Abandoned
- 2019-05-18 KR KR1020207037434A patent/KR20210024492A/ko not_active Ceased
- 2019-05-18 EP EP19810363.2A patent/EP3796928A4/en not_active Withdrawn
- 2019-05-18 US US17/056,449 patent/US20210113703A1/en not_active Abandoned
- 2019-05-18 CN CN201980049813.0A patent/CN112512558A/zh active Pending
- 2019-05-18 CA CA3101097A patent/CA3101097A1/en active Pending
- 2019-05-18 WO PCT/US2019/033012 patent/WO2019231725A2/en not_active Ceased
- 2019-05-18 JP JP2020565929A patent/JP2021525711A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525711A5 (https=) | ||
| EP3998077B1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| US10266816B2 (en) | Carrier for targeting nerve cells | |
| CN101675067B (zh) | 肽组合物的修饰以提高稳定性和递送效率 | |
| JP4484969B2 (ja) | ストレスタンパク質を含む組成物を使用する免疫応答 | |
| US12059454B2 (en) | Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders | |
| US20100093640A1 (en) | Ace-inhibitory peptides from whey and methods for providing the same | |
| NZ591612A (en) | Prevention, treatment and diagnosis of p.gingivalis infection with peptides | |
| CA2482598A1 (en) | Peptide inhibitors of protein kinase c | |
| JP5002603B2 (ja) | 新規なペプチド及びこれの用途 | |
| JP2010525806A5 (https=) | ||
| RU2006145899A (ru) | Ферменты для фармацевтического применения | |
| JP2011518179A5 (https=) | ||
| JP2005053930A5 (https=) | ||
| US20130172229A1 (en) | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences | |
| AR123788A1 (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| CN110891612A (zh) | 蛋白质药物与p/a肽的缀合物 | |
| JP2004533250A5 (https=) | ||
| JP2020037538A5 (https=) | ||
| JP2004538320A5 (https=) | ||
| JP2020117504A5 (https=) | ||
| KR20210093958A (ko) | 미토콘드리아 질환을 표적으로 하는 유사체 | |
| CN101808655B (zh) | 衍生自纤溶酶原激活物抑制剂-1的肽和其应用 | |
| CA2549185A1 (en) | Peptide inhibiting angiotensin converting enzyme | |
| JP2023546383A5 (https=) |